Skip to main content
. 2022 Jul 22;41(1):107–116. doi: 10.1200/JCO.22.00430

FIG 1.

FIG 1.

PFS according to treatment arms (VEL-throughout v placebo [control]) and KELIM (favorable or unfavorable) in cohort of patients operated with (A) PDS and (B) neoadjuvant chemotherapy and IDS. IDS, interval debulking surgery; KELIM, elimination rate constant K; NA, not available; PDS, primary debulking surgery; PFS, progression-free survival; VEL, veliparib.